We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The novel coronavirus is forcing people to clean up their act, and Clorox (CLX - Free Report) is leading the charge. The panic buying of Clorox’s cleaning supplies and consumer staples led to the stock’s initial pandemic driven rally, but I think this uptick in sales is going to be more long-term than the market is pricing in. Analysts are pushing their EPS estimates up for the next three years propelling CLX into a Zacks Rank #1 (Strong Buy).
This pandemic is changing society and the way we operate. The world is going to become much more germ sensitive. Being a “germ freak” is going to be the new norm, and Clorox stands to gain. The panic buying that Clorox has seen this quarter is just the beginning of the topline growth to come.
Business Overview
Clorox is a global brand with a diverse portfolio of products that goes far beyond its disinfectant wipes. This enterprise is a category leader in charcoal, bleach, water filtration, premium trash, wipes, and even salad dressing. One of Clorox’s family of products can be found in 9 out of 10 US homes and a growing international presence (roughly 15% of sales and growing).
The firm’s portfolio is separated into 4 segments: cleaning (34% of sales), household (30%), lifestyle (20%), and international (16%). Cleaning makes up the majority of Clorox’s bottom line, and I suspect that this segment will be the company’s biggest growth driver in our novel “germ freak” society.
The company is dedicated to driving shareholder returns with consistent share price appreciation, stock buyback programs, and a cushy 2.5% dividend yield that has grown annually for the past 2 decades. According to the firm’s most recent investor presentation, over the past 5 years, CLX has driven shareholder returns of 91%, far outpacing the S&P 500’s 66% and its lagging cohort’s 50%.
Risk
Despite Clorox’s category leadership in most of its segments, it is competing with private-label products, that are typically less expensive. Some bargain shoppers may choose the private label products in these uncertain times, but Clorox still has the brand advantage.
The stock's low beta suggests that even in times of economic uncertainty, people will still choose Clorox products over competitors because they know it’s a brand they can trusted. During the pandemic panic, I suspect that Clorox’s brand trust & loyalty will continue to drive its growth.
CLX is trading at its highest forward P/E multiple in over two decades, which gives this stock some added risk. I think that this rich multiple is mostly justified for this high-yielding safe-haven stock.
Stock Performance
CLX has traded all over the board since the pandemic panic began, falling down below $160, then surging up over $210. The stock has since settled down to the mid $160s.
The Clorox Company Price, Consensus and EPS Surprise
CLX is a safety play for your portfolio and provides long-term potential. I am not banging on the table screaming buy at this price, but I think that this high yielding equity could help curb some of your portfolio’s market risk in these uncertain times.
The world is going to be much more germ sensitive in the years to come, and Clorox is well-positioned for this consumer transition.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bull Of The Day: Clorox (CLX)
The novel coronavirus is forcing people to clean up their act, and Clorox (CLX - Free Report) is leading the charge. The panic buying of Clorox’s cleaning supplies and consumer staples led to the stock’s initial pandemic driven rally, but I think this uptick in sales is going to be more long-term than the market is pricing in. Analysts are pushing their EPS estimates up for the next three years propelling CLX into a Zacks Rank #1 (Strong Buy).
This pandemic is changing society and the way we operate. The world is going to become much more germ sensitive. Being a “germ freak” is going to be the new norm, and Clorox stands to gain. The panic buying that Clorox has seen this quarter is just the beginning of the topline growth to come.
Business Overview
Clorox is a global brand with a diverse portfolio of products that goes far beyond its disinfectant wipes. This enterprise is a category leader in charcoal, bleach, water filtration, premium trash, wipes, and even salad dressing. One of Clorox’s family of products can be found in 9 out of 10 US homes and a growing international presence (roughly 15% of sales and growing).
The firm’s portfolio is separated into 4 segments: cleaning (34% of sales), household (30%), lifestyle (20%), and international (16%). Cleaning makes up the majority of Clorox’s bottom line, and I suspect that this segment will be the company’s biggest growth driver in our novel “germ freak” society.
The company is dedicated to driving shareholder returns with consistent share price appreciation, stock buyback programs, and a cushy 2.5% dividend yield that has grown annually for the past 2 decades. According to the firm’s most recent investor presentation, over the past 5 years, CLX has driven shareholder returns of 91%, far outpacing the S&P 500’s 66% and its lagging cohort’s 50%.
Risk
Despite Clorox’s category leadership in most of its segments, it is competing with private-label products, that are typically less expensive. Some bargain shoppers may choose the private label products in these uncertain times, but Clorox still has the brand advantage.
The stock's low beta suggests that even in times of economic uncertainty, people will still choose Clorox products over competitors because they know it’s a brand they can trusted. During the pandemic panic, I suspect that Clorox’s brand trust & loyalty will continue to drive its growth.
CLX is trading at its highest forward P/E multiple in over two decades, which gives this stock some added risk. I think that this rich multiple is mostly justified for this high-yielding safe-haven stock.
Stock Performance
CLX has traded all over the board since the pandemic panic began, falling down below $160, then surging up over $210. The stock has since settled down to the mid $160s.
The Clorox Company Price, Consensus and EPS Surprise
The Clorox Company price-consensus-eps-surprise-chart | The Clorox Company Quote
Take Away
CLX is a safety play for your portfolio and provides long-term potential. I am not banging on the table screaming buy at this price, but I think that this high yielding equity could help curb some of your portfolio’s market risk in these uncertain times.
The world is going to be much more germ sensitive in the years to come, and Clorox is well-positioned for this consumer transition.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>